Chemotherapy is the abbreviation of chemical medicine treatment. It can kill cancer cells by using chemical medicine. Chemotherapy is one of the most effective methods to treat cancer, and it is called the three major treatment methods together with surgery and radiotherapy. Surgery and radiotherapy belong to local treatment, which is only effective for tumors at the treatment site. It is difficult to give full play to the effective treatment for potential metastatic lesions (cancer cells have actually metastasized, but because the current technical means are limited in clinical detection and detection) and cancers with clinical metastasis. Chemotherapy is a means of systemic treatment. No matter what way of Drug Administration (oral, intravenous and body cavity administration, etc.), chemotherapy drugs will spread throughout most organs and tissues with blood circulation. Therefore, chemotherapy is the main treatment for some tumors with general dissemination tendency and those with metastasis.
|Cat. No.||Product Name||CAS No.||Information|
A potent, orally active, long-acting human NK-1 receptor (substance P receptor) antagonist with IC50 of 0.09 nM; blocks NK-1 agonist-induced foot tapping response in gerbils and shows antiemetic actions in the ferret against cisplatin challenge; has the potentiation for the treatment of peripheral pain, migraine, chemotherapy-induced emesis, and various psychiatric disorders.
A novel combretastatin A-4 derivative and tubulin polymerization inhibitor that strongly stanches tumour blood flows and inhibits growth of tumours developing in various tissues and organ; a vascular-disrupting agent under clinical investigation combined with cisplatin/docetaxel or carboplatin/paclitaxel in patients with advanced solid tumors.
A chemotherapeutic prodrug of 5-flourouracil (5-FU) used in the treatment of cancers; a thymidylate synthase inhibitor.
A first-in-class anticancer quinolone derivative that intercalates DNA and inhibits Topoisomerase II; exhibits proliferation inhibition of AML cell lines MV4-11 and HL-60 with IC50 of 95 nM and 884 nM, respectively.
An orally available, nucleoside analog prodrug of CNDAC that interferes with DNA synthesis by causing single-strand DNA breaks; induces arrest of the cell division cycle at G2 phase, demonstrates potent anti-tumor activity in both blood and solid tumors.
A classical multitargeted antifolate that inhibits multiple folate-requiring enzymes TS/DHFR/GARFT with Ki of 1.3/7.2/65 nM respectively; increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma.
Satraplatin (BMS-182751, BMY-45594, JM-216) is a platinum-based antineoplastic agent that binds to guanine residues in DNA, inhibits DNA replication and transcription, leads to subsequent apoptosis; shows similar cytotoxicity and pattern of cytotoxicity to cisplatin against human ovarian carcinoma cell lines (IC50=1.7 uM); shows antitumor selectivity far superior to cisplatin, carboplatin, or tetraplatin in vivo; orally active.
A novel topoisomerase II (Topo II) inhibitor and DNA intercalator that induces apoptotic signaling by blocking the binding of Topo II to DNA.
A taxol derivative with antitumor, antiproliferative properties.
An inhibitor of dihydropyrimidine dehydrogenase, degrades pyrimidine including 5-fluorouracil in the blood; inhibits homologous recombination.
No.1378 West Wenyi Road, Yuhang District, HangZhou, Zhejiang, China